OP23 Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis
Saranya Sridhar(Sanofi (France)), Patrick Branigan(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Teresa Lee(Columbia University Irving Medical Center), Darren Ruane(Regeneron (United States)), K H G Huang(Janssen (Germany)), Bram Verstockt(Universitair Ziekenhuis Leuven), Daniel Cua(Janssen (Germany)), Tom C. Freeman(Johnson & Johnson (United States)), Andrew Hart(Janssen (Germany)), David T. Rubin(University of California System), S Venkat(Janssen (Germany)), Bradford L. McRae(Janssen (Belgium)), M Vetter(Janssen (United States)), Daniel Horowitz(Janssen (Germany)), Matthew Germinaro(Johnson & Johnson (United States)), Christopher Sisk(Janssen (Germany)), Dawn Waterworth(GlaxoSmithKline (United States))
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k